This is not surprising given the fact that anti-PD-1 antibodies, the most commonly used ICBs in lung cancer, only “fix” one specific step in the cancer immunity cycle, which is alleviating T cell paralysis in the TME. This evidence concerns the gene PDCD1 and lung cancer.